Requires cannabinoid edibles to be individually packaged and allows up to 10 milligrams of adult use cannabinoid per individual cannabinoid edible.
SB 1548 revises Oregon’s marijuana packaging and potency rules, with a particular focus on cannabinoid edibles and other cannabinoid products. The bill directs the Oregon Liquor and Cannabis Commission (OLCC), in consultation with the Oregon Health Authority and the State Department of Agriculture, to adopt packaging standards intended to protect public health and safety. Among other things, it requires child-resistant packaging, prohibits misleading or youth-appealing marketing, and adds a new requirement that each cannabinoid edible in a package be individually wrapped, except for potable liquids.
The measure also sets statewide serving and package limits for adult-use cannabinoid products. It requires OLCC rules to allow up to 100 milligrams of adult-use cannabinoid per package of cannabinoid edibles, but no more than 10 milligrams per individual edible. The bill preserves separate rulemaking for medical marijuana consumers and allows the commission to tailor standards by product type, while also requiring the agency to consider environmental impacts and consumer costs when adopting packaging rules.
In addition to the packaging and potency changes, the bill updates Oregon’s marijuana statutes to require that products sold or transferred by licensed marijuana retailers and medical marijuana dispensaries comply with the new standards. The amendments apply to marijuana items sold or transferred to final consumers on or after January 1, 2027, and the operative date for the new requirements is also January 1, 2027. The bill takes effect 91 days after adjournment sine die, and it authorizes OLCC to begin preparatory rulemaking before the operative date.
The general sentiment around the bill appears mostly supportive, especially in committee, where it advanced unanimously on a do-pass-with-amendments vote (5-0). It later passed Senate third reading 22-5, suggesting broader support but not unanimity. The available record does not include committee testimony, so the discussion context is limited, but the vote pattern indicates the bill was viewed favorably by a majority of senators.
The main points of contention appear to center on regulatory burden and the balance between public health protections and industry flexibility. The bill’s requirements for individual wrapping, packaging restrictions, and potency caps could raise compliance costs for producers and retailers, while supporters likely view those same provisions as necessary to reduce youth access and improve consumer safety. The bill also reflects a policy choice to standardize adult-use edible dosing while preserving some flexibility for medical marijuana patients and allowing OLCC to consider cost and environmental effects.
SB 1548 amends ORS 475C.612 and 475C.620 to impose new statewide packaging and serving-size standards for marijuana items, especially cannabinoid edibles. It requires OLCC to adopt rules mandating child-resistant packaging, anti-youth marketing protections, and individual wrapping for each edible in a package, while also setting a maximum of 10 milligrams of adult-use cannabinoid per edible and 100 milligrams per package. The bill applies these changes to products sold or transferred to final consumers on or after January 1, 2027, and it directs both OLCC and the Oregon Health Authority to align medical and adult-use rules with the new standards.
The bill appears to have received generally favorable treatment in the Senate, advancing unanimously out of committee on a do-pass-with-amendments recommendation and later passing third reading with a 22-5 vote. That pattern suggests broad agreement on the need for stronger packaging and dosing rules, though not complete consensus. Because no committee transcript was provided, the record does not show detailed debate, but the voting history indicates the measure was viewed positively overall with some dissent on the floor.
The likely areas of disagreement are the bill’s regulatory scope and its effects on the cannabis market. Opponents or skeptics may object to the added packaging requirements, the individual-wrapping mandate, and the potency limits as costly or burdensome for businesses, while supporters likely emphasize child safety, reduced youth appeal, and clearer dosing. Another possible point of tension is the bill’s balance between adult-use restrictions and medical marijuana access, since the measure preserves separate standards for registry card holders but still expands rulemaking authority over both medical and recreational products.